Stock DCL CUU LONG PHARMACEUTICAL
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cuu Long Pharmaceutical

Equities

DCL

VN000000DCL1

Pharmaceuticals

End-of-day quote Ho Chi Minh S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
28,700 VND 0.00% Intraday chart for Cuu Long Pharmaceutical -1.37% +14.80%
22/05 Cuu Long Pharmaceutical Joint Stock Company Announces Board Appointments CI
24/04 Cuu Long Pharmaceutical Joint Stock Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,31,387 15,91,319 14,32,187 23,41,546 17,89,505 18,26,026
Enterprise Value (EV) 1 7,13,419 16,70,824 17,09,928 25,07,773 21,41,450 23,38,444
P/E ratio 42.4 x 22.5 x 26.1 x 26.6 x 15.4 x 29.6 x
Yield - - - - - -
Capitalization / Revenue 0.66 x 2.12 x 2.13 x 3.33 x 1.76 x 1.6 x
EV / Revenue 0.89 x 2.22 x 2.55 x 3.56 x 2.11 x 2.04 x
EV / EBITDA 13.8 x 32 x 22.4 x 20.7 x 12.9 x 21.5 x
EV / FCF -3.24 x -14.1 x -3.38 x -8.06 x -2.63 x -12.5 x
FCF Yield -30.9% -7.07% -29.6% -12.4% -38% -8.03%
Price to Book 0.71 x 1.9 x 1.59 x 2.41 x 1.3 x 1.27 x
Nbr of stocks (in thousands) 56,833 56,833 56,833 58,833 73,041 73,041
Reference price 2 9,350 28,000 25,200 39,800 24,500 25,000
Announcement Date 15/03/19 30/03/20 31/03/21 28/01/22 30/03/23 28/03/24
1VND in Million2VND
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 8,04,180 7,52,014 6,71,246 7,03,634 10,15,686 11,43,946
EBITDA 1 51,777 52,255 76,184 1,20,888 1,66,302 1,08,737
EBIT 1 10,752 12,788 47,904 86,781 1,28,285 70,726
Operating Margin 1.34% 1.7% 7.14% 12.33% 12.63% 6.18%
Earnings before Tax (EBT) 1 20,028 1,04,733 85,944 1,10,284 1,41,542 78,111
Net income 1 12,535 88,474 66,391 85,961 1,11,641 61,717
Net margin 1.56% 11.76% 9.89% 12.22% 10.99% 5.4%
EPS 2 220.6 1,244 966.2 1,495 1,591 845.0
Free Cash Flow 1 -2,20,456 -1,18,140 -5,05,849 -3,10,957 -8,14,492 -1,87,823
FCF margin -27.41% -15.71% -75.36% -44.19% -80.19% -16.42%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 15/03/19 30/03/20 31/03/21 28/01/22 30/03/23 28/03/24
1VND in Million2VND
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1,82,032 79,505 2,77,741 1,66,227 3,51,945 5,12,418
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.516 x 1.521 x 3.646 x 1.375 x 2.116 x 4.712 x
Free Cash Flow 1 -2,20,456 -1,18,140 -5,05,849 -3,10,957 -8,14,492 -1,87,823
ROE (net income / shareholders' equity) 1.59% 10.3% 7.43% 8.81% 9.59% 4.37%
ROA (Net income/ Total Assets) 0.46% 0.46% 1.7% 3.03% 4.13% 2.02%
Assets 1 27,53,636 1,90,59,391 38,95,044 28,38,109 27,05,724 30,59,709
Book Value Per Share 2 13,171 14,726 15,863 16,492 18,806 19,610
Cash Flow per Share 2 398.0 255.0 737.0 701.0 724.0 322.0
Capex 1 1,02,686 10,515 1,01,948 1,52,612 2,33,028 2,22,874
Capex / Sales 12.77% 1.4% 15.19% 21.69% 22.94% 19.48%
Announcement Date 15/03/19 30/03/20 31/03/21 28/01/22 30/03/23 28/03/24
1VND in Million2VND
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CUU LONG PHARMACEUTICAL Stock Cuu Long Pharmaceutical
+14.80% 82.37M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DCL Stock
  4. Financials Cuu Long Pharmaceutical